Thirty-Day Outcomes of Young and Middle-Aged Adults Admitted with Severe COVID-19 in Uganda: A Retrospective Cohort Study
Kyagambiddwa et al.
, Thirty-Day Outcomes of Young and Middle-Aged Adults Admitted with Severe COVID-19 in Uganda: A Retrospective..
, Infection and Drug Resistance, doi:10.2147/idr.s405256
This study includes zinc
and vitamin C.
risk of death, 50.0% lower, HR 0.50, p = 0.06, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kyagambiddwa et al., 11 May 2023, retrospective, Uganda, peer-reviewed, mean age 39.0, 15 authors, study period May 2020 - August 2022.
Abstract: Infection and Drug Resistance
open access to scientific and medical research
Open Access Full Text Article
Infection and Drug Resistance
For personal use only.
Thirty-Day Outcomes of Young and Middle-Aged
Adults Admitted with Severe COVID-19 in
Uganda: A Retrospective Cohort Study
Tonny Kyagambiddwa 1,*, Timothy Mwanje Kintu 1,*, Emmanuel Miiro 1,*, Franchesca Nabalamba1,
Gloria Suubi Asiimwe1, Anne Marion Namutebi2, Fardous C Abeya3, Boniface A Lumori3, Isaac Ijuka4,
Rose K Muhindo1,3, Andrew Mutekanga 1,3, Richard Musinguzi 5, Francis Natuhwera6, Joseph Ngonzi1,7,
Edwin Nuwagira 3,8
Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; 2Kabale Regional Referral Hospital, Kabale, Uganda;
Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda; 4Mayanja Memorial Hospital, Mbarara, Uganda; 5Masaka
Regional Referral Hospital, Masaka, Uganda; 6Fort Portal Regional Referral Hospital, Fort Portal, Uganda; 7Department of Obstetrics and Gynecology,
Mbarara University of Science and Technology, Mbarara, Uganda; 8Tuberculosis Treatment Unit, Mbarara Regional Referral Hospital, Mbarara, Uganda
*These authors contributed equally to this work
Correspondence: Tonny Kyagambiddwa; Edwin Nuwagira, Mbarara University of Science and Technology, Tel +256782980116; +256779096887,
Email email@example.com; firstname.lastname@example.org
Background: There is scarcity of data regarding young and middle-aged adults hospitalized with severe Corona Virus Disease 2019
(COVID-19) in Africa. In this study, we describe the clinical characteristics and 30-day survival among adults aged 18 to 49 years
admitted with severe COVID-19 in Uganda.
Methods: We reviewed treatment records of patients admitted with severe COVID-19 across five COVID-19 treatment units (CTU)
in Uganda. We included individuals aged 18 to 49 years, who had a positive test or met the clinical criteria for COVID-19. We defined
severe COVID-19 as having an oxygen saturation <94%, lung infiltrates >50% on imaging and presence of a co-morbidity that
required admission in the CTU. Our main outcome was the 30-day survival from the time of admission. We used a Cox proportional
hazards model to determine the factors associated with 30-day survival at a 5% level of significance.
Results: Of the 246 patient files reviewed, 50.8% (n = 125) were male, the mean ± (standard deviation) age was 39 ± 8 years, majority
presented with cough, 85.8% (n = 211) and median C-reactive protein (interquartile range) was 48 (47.5, 178.8) mg/L. The 30-day
mortality was 23.9% (59/246). At admission, anemia (hazard ratio (HR): 3.00, 95% confidence interval (CI), 1.32–6.82; p = 0.009) and
altered mental state (GCS <15) (HR: 6.89, 95% CI: 1.48–32.08, p = 0.014) were significant predictors of 30-day mortality.
Conclusion: There was a high 30-day mortality among young and middle-aged adults with severe COVID-19 in Uganda. Early
recognition and targeted management of anemia and altered consciousness are needed to improve clinical outcomes.
Keywords: COVID-19, Uganda, mortality, young and middle-aged adults
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.